Novel cognitive enhancer ST101 enhances acetylcholine release in mouse dorsal hippocampus through T-type voltage-gated calcium channel stimulation
-
- Yamamoto Yui
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Japan
-
- Shioda Norifumi
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Japan
-
- Han Feng
- Institute of Pharmacology and Toxicology and Biochemical Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, China
-
- Moriguchi Shigeki
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Japan
-
- Fukunaga Kohji
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Japan
書誌事項
- タイトル別名
-
- The Novel Cognitive Enhancer ST101 Enhances Acetylcholine Release in Mouse Dorsal Hippocampus Through T-type Voltage-Gated Calcium Channel Stimulation
この論文をさがす
説明
We recently developed a novel cognitive enhancer, ST101 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one), that activates T-type voltage-gated calcium channels (VGCCs). Here, we address whether T-type VGCC activation with ST101 mediates its cognitive effects in vivo and the relevance of T-type VGCC activation to acetylcholine (ACh) release in the hippocampus. Acute intraperitoneal administration of ST101 (1 mg/kg, i.p.) improved memory-related behaviors in both olfactory bulbectomized (OBX) and scopolamine-treated mice. Effects of ST101 administration were abolished by both intraperitoneal and intracerebroventricular pre-administration of the T-type VGCC inhibitor mibefradil. Acute administration of ST101 enhanced basal and nicotine-induced ACh release in the dorsal hippocampus in both OBX and sham-treated mice. Enhanced ACh release was abolished by infusion with mibefradil (10 μM) but not with the L-type VGCC inhibitor nifedipine (10 μM). As expected, significantly reduced CaMKIIα, PKCα, and ERK phosphorylation was restored by acute ST101 administration in the OBX mouse hippocampal CA1 region. Enhancement of CaMKIIα and PKCα but not ERK phosphorylation was inhibited by mibefradil (20 mg/kg, i.p.) preadministration. Increased CaMKIIα and PKCα phosphorylation was confirmed by increased phosphorylation of GluR1, synapsin I, and NR1. Taken together, stimulation of T-type VGCCs is critical for the enhanced hippocampal ACh release and improved cognitive function seen following ST101 administration.
収録刊行物
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 121 (3), 212-226, 2013
公益社団法人 日本薬理学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390001205180631424
-
- NII論文ID
- 10031165466
-
- NII書誌ID
- AA11806667
-
- COI
- 1:STN:280:DC%2BC3svitFCktw%3D%3D
-
- ISSN
- 13478648
- 13478613
-
- NDL書誌ID
- 024351368
-
- PubMed
- 23449490
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- NDLサーチ
- Crossref
- PubMed
- CiNii Articles
- KAKEN
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可